1. Taiwan Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
SunWay Biotech Co., Ltd.

SunWay Biotech Co., Ltd.

TTPEX:1271
59.70
TWD
+0.20
(+0.34%)
3.75BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.45
9.9
11.31
21.11
18.99
16.07
16.48
- -
Basic EPS, GAAP
1.21
3.96
5.01
1.49
1.53
1.96
1.68
- -
Free Cash Flow per Basic Share
2.36
5.67
4.49
1.99
0.32
0.55
1.97
- -
Dividend per Share
- -
- -
2.76
0.32
1.42
0.98
1.33
- -
Book Value per Share
8.31
13.78
16.14
8.44
52.98
54.03
54.27
69.42
Tangible Book Value per Share
7.88
13.39
15.79
7.95
12.31
13.97
14.72
14.06
Basic Weighted Avg Shares
32
32
34
20
30
60
60
62
Sales/Revenue/Turnover
172
314
380
425
571
970
993
- -
Operating Margin (%)
24.45
40.03
44.09
9.14
9.29
14.53
10.48
- -
Depreciation Expense
22
20
20
8
25
84
71
- -
Net Income, GAAP
38
126
169
30
46
119
102
- -
Effective Tax Rate (%)
3.42
- -
0.29
20.91
17.41
16.56
12.07
- -
Profit Margin (%)
22.21
39.98
44.36
7.06
8.07
12.22
10.22
- -
Working Capital
186
388
468
253
609
602
303
740
LT Debt
2
- -
- -
3
248
227
624
803
Total Equity
279
465
547
288
3,202
3,265
3,264
4,174
Return on Invested Capital (%)
- -
32.27
31.78
6.64
2.23
3.33
2.37
- -
Return on Capital (%)
- -
32.29
32
6.4
2.46
3.51
2.91
- -
Return on Common Equity (%)
- -
33.93
33.56
7.22
2.64
3.67
3.11
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
326
263
846
LT Borrowings
- -
409
584
LT Finance Leases
220
215
220
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
60
60
Market Capitalization
3,865
3,569
3,749

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
1,196
788
2,243
Cash, Cash Equivalents & STI
681
301
726
Accounts Receivable, Net
224
274
647
Inventories
263
190
749
Total Current Liabilities
620
485
1,503
Payables & Accruals
- -
- -
- -
ST Debt
326
263
846
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
196.79%
-0.04%
Free Cash Flow
- -
66.66%
257.59%
Net Income, GAAP
- -
29.66%
-14.4%
Sales/Revenue/Turnover
- -
27.86%
2.38%
Total Cash Common Dividend
- -
- -
35.24%

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
970
2025
- -
- -
993
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.96
2025
- -
- -
1.68
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.98
2025
- -
- -
1.33
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chia Yueh Pan
Full Time Employees
58
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
No. 139, Xing ai Road Taipei TP Taiwan 11494
IPO Date
Jan 18, 2021
Website
sunway.cc
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
SunWay Biotech Co., Ltd. (1271.TWO) engages in the research, development, manufacturing, and marketing of functional biotech ingredients and related products for the nutraceutical and health supplement industries. The company offers core products including ANKASCIN 568-R, a patented red yeast rice extract from Monascus purpureus NTU 568 that supports blood lipid, glucose, and pressure regulation without monacolin K; Vigiis 101-LAB, a probiotic strain Lactobacillus paracasei subsp. paracasei NTU 101 for immune modulation, gut health, and lipid reduction; and additional offerings such as ExoBDNF, XtraMyo, and branded lines like HCW Dr. B, Boost Effervescent Tablets, and agency products including Eisai, Boiron, and Shionogi pharmaceuticals. It provides end-to-end services encompassing ingredient development, CDMO/CMO contract manufacturing, proprietary branded products, and brand licensing. SunWay Biotech operates primarily from its headquarters and manufacturing facility in Xizhi District, New Taipei City, Taiwan, with global reach through exports to the United States, Europe, Japan, and other markets; the company was founded in 2007. Recent developments include a strategic NT$650 million investment in August 2025 to acquire a 30% stake in Wonders Company Ltd., forming a multi-brand nutraceuticals platform integrating probiotics and red yeast rice expertise; a 2023 partnership with Gnosis by Lesaffre to launch MenaQ7 Metabolic, combining ANKASCIN 568-R with vitamin K2 MK-7 for cardiometabolic health; and ANKASCIN 568-R receiving Taiwan's SNQ Bronze Award in 2024 along with NutraIngredients USA Awards finalist recognition.